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Encephalitis causes high rates of illness and death, yet 
its epidemiology remains poorly understood. To improve in-
cidence estimates in England and inform priority setting and 
treatment and prevention strategies, we used hospitaliza-
tion data to estimate incidence of infectious and noninfec-
tious encephalitis during 2005–2009. Hospitalization data 
were linked to a dataset of extensively investigated cases 
of encephalitis from a prospective study, and capture–re-
capture models were applied. Incidence was estimated 
from unlinked hospitalization data as 4.32 cases/100,000 
population/year. Capture–recapture models gave a best es-
timate of encephalitis incidence of 5.23 cases/100,000/year, 
although the models’ indicated incidence could be as high 
as 8.66 cases/100,000/year. This analysis indicates that the 
incidence of encephalitis in England is considerably higher 
than previously estimated. Therefore, encephalitis should 
be a greater priority for clinicians, researchers, and public 
health officials.
Encephalitis is associated with severe illness, apprecia-ble mortality rates, and high health care costs (1), but 
its epidemiology remains poorly understood (2). The sole 
previous incidence estimate for encephalitis in England 
of 1.5 cases per 100,000 population per year was for vi-
ral encephalitis only and was based on hospitalization data 
from 1989–1998 (3). Incidence should be understood; as 
an increasing number of viruses have been found to cause 
encephalitis in humans, more cases might be found among 
the high proportion of cases of unknown etiology (2,4–6). 
Climate change and increasing international travel raise 
the possibility of wider geographic spread of microbes, 
which may have important public health implications. 
Clarifying incidence is also important clinically with the 
increasing recognition of novel immune-mediated forms 
of encephalitis, especially because treatment is available 
if started early (7–9).
Although encephalitis is a statutorily notifiable disease 
in England, it is grossly underreported, making notifica-
tion data unsuitable for incidence estimation (3). Almost 
all encephalitis case-patients require hospitalization; thus, 
routinely collected hospitalization data provide a possible 
source of data from which to estimate incidence. How-
ever, diagnosis of encephalitis is complicated by the lack 
of a standard case definition or pathognomonic symptoms 
and signs. Many patients with suspected encephalitis ulti-
mately are found to have conditions with neurologic signs 
that mimic encephalitis. We recently reported on the Public 
Health England (PHE) study, the largest population-based 
prospective cohort of encephalitis patients to date in Eng-
land (10). Data from this study, which included exhaustive 
multistage diagnostic investigations of cases, provided a 
unique opportunity to complement routinely collected hos-
pitalization data to enable detailed analyses of encephalitis 
incidence in England. We linked the 2 data sources and per-
formed capture–recapture analyses to estimate the number 
of encephalitis cases in England attributable to infectious 
and noninfectious causes.
Methods
Data Sources
PHE Study
Patients with encephalitis were recruited over a 2-year 
period from 24 hospitals in 3 regions of England. Suspect-
ed cases were actively identified and investigated by us-
ing extensive systematic laboratory testing, a specific case 
definition, and classification of cases by a multidisciplinary 
expert panel. Details are described elsewhere (10).
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Hospital Episode Statistics 
These routinely collected data include all admissions 
to National Health Service hospitals in England, recorded 
by financial year (April–March). Each record represents 
an episode, a continuous period of hospital care under 1 
consultant; patients may have multiple episodes within 1 
hospitalization. For example, 2 separate records and hence 
episodes are generated in Hospital Episode Statistics (HES) 
if a patient is initially admitted to Accident and Emergency 
and subsequently transferred to a neurology ward. Each ep-
isode has up to 20 diagnoses, recorded by using codes from 
the International Classification of Diseases, 10th Revision 
(http://apps.who.int/classifications/icd10/browse/2010/en). 
The primary diagnosis usually reflects the main reason for 
hospital admission. However, incident encephalitis cases 
can also be recorded in secondary diagnostic fields if the 
primary diagnosis was a symptom or sign, if encephalitis 
was initially misdiagnosed, or if encephalitis developed 
during hospital admission.
All episodes with an admission date from April 1, 2005 
through February 28, 2009 containing an encephalitis code 
(online Technical Appendix Table 1, wwwnc.cdc.gov/EID/
article/19/9/13-0064-Techapp1.pdf) in any diagnostic field 
were obtained from HES. Data were obtained in May 2009; 
data from 2008–2009 were provisional and did not include 
cases for March 2009.
Data with an encephalitis code in any diagnostic field 
(the main analysis), as well as data with an encephalitis 
code in the primary diagnostic field only, were examined 
(see Table 1 for definition of numerators). Mid-2007 resi-
dent population estimates for England from the Office for 
National Statistics were used as denominators. Bootstrap 
resampling of hospital trusts and 1,000 repetitions were 
used to obtain 95% CIs.
Rates of HES encephalitis admissions were calculated 
by year, sex, age, and region by using data with an encephali-
tis code in any diagnostic field. We performed multivariable 
negative binomial regression analyses to investigate how 
the rate of incident encephalitis admissions varied with 
each variable.
Capture–Recapture Analyses
For these analyses, PHE and HES data were restricted 
to patients admitted from November 1, 2006, through Oc-
tober 31, 2007, when all 24 hospitals in the PHE study were 
recruiting simultaneously, and to the 19 HES hospital trusts 
that included the 24 PHE study hospitals (hospital data are 
coded to trust level in HES). Cases were linked by date of 
birth, date of admission, sex, and postcode. Fuzzy (approx-
imate) matching was also performed to allow for possible 
coding errors in the matching variables.
For 2 PHE study hospitals, the corresponding HES 
hospital trust included another hospital that had not partici-
pated in the PHE study and could have admitted encepha-
litis patients (e.g., had an accident and emergency depart-
ment). Data from these 2 PHE hospitals and HES trusts 
were excluded in sensitivity analyses to assess their effect 
on capture–recapture estimates.
We determined the number of cases that matched be-
tween the 2 datasets and the numbers included only in the 
PHE study and only in the HES data. Fisher exact and χ2 
tests were used to compare characteristics (including age, 
sex, ethnic group, and etiology) of PHE study cases that 
matched and did not match to HES cases and character-
istics of matched and unmatched HES admissions. Other 
comparisons between matched and unmatched HES cases 
included method of admission (e.g., elective or emergen-
cy), consultant specialty, and discharge destination. The 
2-sample Wilcoxon rank sum test was used to compare 
length of hospital stay between matched and unmatched 
HES admissions.
Two-sample capture–recapture analyses were per-
formed. The Lincoln-Peterson formula was used to esti-
mate the number of encephalitis cases that occurred from 
November 1, 2006, through October 31, 2007, for the 24 
included sites, which comprised the number listed in ei-
ther source plus the estimated number of unlisted cases 
(11). The completeness of ascertainment (%) for each data 
source was estimated by using this total capture–recapture 
estimate. CIs were calculated from the standard errors of 
coefficients obtained from fitting a log linear model. To 
assess potential violation of the capture–recapture as-
sumption that every patient has the same probability of 
being ascertained by each source, data were stratified by 
2 characteristics that could affect the likelihood of being 
ascertained: age (<18 years and >18 years) and region 
(South West, London, and North West). Capture–recap-
ture analyses were rerun for each stratum, and the results 
were combined and compared with those from unstrati-
fied analyses.
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Table 1. Definition of numerator for encephalitis incidence 
estimates, England 
First-ever episode* Subsequent episodes 
Encephalitis code in 
any diagnostic field 
(1–20) 
Subsequent encephalitis code/s 
represented a different etiology to that 
recorded for the first-ever episode; for 
identical codes, both were in the primary 
diagnostic field and the end date of the 
first episode and start date of the 
subsequent spell were >6 mo apart 
Encephalitis code in 
primary diagnostic 
field only 
Subsequent encephalitis codes were also 
in the primary diagnostic field and 
represented a different etiology to that 
recorded for the first-ever episode; for 
identical codes, both were in the primary 
diagnostic field and the end date of the 
first spell and start date of the 
subsequent spell were >6 mo apart 
*Refers to the first-ever episode within this dataset. 
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Another key assumption of capture–recapture analy-
ses is the absence of false-positive cases, which could have 
arisen in the HES data because of misdiagnosis of nonen-
cephalitis cases or coding errors. Sensitivity analyses were 
thus conducted by using a range (30%–80%) of positive 
predictive values (PPVs) for an HES encephalitis code to 
reduce the number of HES-only cases included in capture–
recapture models. Within this range of PPVs, we focused 
on a best estimate of 54%, based on the proportion of pa-
tients with suspected cases of encephalitis who were ini-
tially screened in the PHE study and ultimately included in 
the study (203/379), assuming that all screened PHE cases 
would have been coded as encephalitis in HES (10).
HES admissions from November 1, 2006, through 
October 31, 2007, for the trusts that corresponded to PHE 
study hospitals represented 19% of all encephalitis admis-
sions in England. We assumed the accuracy of coding in 
these trusts is generalizable to all England admissions; 
therefore, we multiplied the capture–recapture estimate of 
the number of cases in these trusts by 5.3 to obtain ascer-
tainment-adjusted national incidence estimates.
Results
HES Incidence
Annual incidence estimates are displayed in the Figure. 
On the basis of HES data with an encephalitis code in any 
diagnostic field, the overall mean incidence was 4.32 cas-
es/100,000 population/year (95% CI 3.74–4.96/100,000/
year). Two percent of patients (n = 216) had >1 encepha-
litis admission during the study period; incidence did not 
change (4.20 cases/100,000/year) when subsequent admis-
sions of these patients were excluded from the analysis. 
By using data restricted to the primary diagnostic field, the 
overall mean incidence was 2.75 cases/100,000/year (95% 
CI 2.39 cases–3.10/100,000/year).
Results of multivariable analyses showed that, com-
pared with 2005–2006, incidence in all subsequent years 
was slightly higher but with little evidence of a trend (p = 
0.19). The incidence rate was highest among patients <1 
and >65 years of age. The rate for female patients (adjusted 
for year, age, and region) was 8% less than the adjusted 
rate for male patients (online Technical Appendix Table 2)
Capture–recapture Analyses
For the defined 1-year period, the overall number of 
incident encephalitis admissions recorded in the relevant 
HES trusts was almost 4 times the number of cases in 
the PHE study (439 admissions vs. 113 cases) by using 
HES data with an encephalitis code in any diagnostic field 
and was 2.5 times the number (287 admissions vs. 113 
cases) when HES data were restricted to the primary di-
agnostic field.
Fifty-nine (52%) of 113 PHE study cases matched to 
HES cases, and 1 case was linked by using fuzzy matching. 
Fifty-four cases were registered only by the PHE study and 
380 were registered only by HES. The characteristics of the 
59 matched HES cases and the 380 unmatched HES cases 
are presented in Table 2. A high proportion (91%) of en-
cephalitis cases of unknown etiology indicated in the HES 
data were unmatched. Of the 125 case-patients admitted 
electively and 38 case-patients treated by neurosurgery in 
the HES data, 95% and 100%, respectively, did not match 
the PHE data; unmatched HES patients with admissions 
also had a shorter length of hospital stay (11 vs. 31 days; 
p<0.001; Table 2). The results were similar when HES data 
restricted to the primary diagnostic field were used (data 
not shown).
Heterogeneity in etiology was evident between un-
matched PHE cases and HES-matched PHE cases (p = 
0.01; Table 2). A high proportion (80%) of bacterial en-
cephalitis cases in the PHE data were unmatched, whereas 
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Figure. Rate of incident encephalitis 
admissions by year per 100,000 
population, England, April 2005–
February 2009. Values indicated are rate 
(95% CI). Overall rate for all diagnostic 
fields: 4.32 (3.74–4.96); for primary 
field only: 2.75 (2.39–3.10).
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a lower proportion of PHE cases designated as immune-
mediated encephalitis (22%) or herpes simplex virus (HSV) 
encephalitis (33%) were unmatched. Further comparison of 
the etiologic classification of the 59 cases that matched in 
the 2 datasets showed some discrepancies (online Technical 
Appendix Table 3); 1 HES varicella zoster virus encepha-
litis case was diagnosed as HSV encephalitis in the PHE 
study, and 2 “other mixed” HES cases were diagnosed as 
immune-mediated in the PHE data. The 21 HES encephali-
tis admissions of unspecified etiology that matched to PHE 
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Table 2. Characteristics of HES-only admissions compared with those that matched to PHE study cases and characteristics of cases 
included in the PHE study only compared with those of PHE study cases that matched to HES, England, November 1, 2006–October 
31, 2007* 
Characteristics 
HES  PHE study 
HES only,  
n = 380 
Matched,†  
n = 59  p value  
PHE only,  
n = 54 
Matched,‡  
n = 59 p value§ 
Age group†        
 <1 14 (77.8) 4 (22.2) 0.11§  5 (55.6) 4 (44.4) 0.22 
 1–4 23 (71.9) 9 (28.1)   5 (38.5) 8 (61.5)  
 5–19 51 (86.4) 8 (13.6)   6 (40) 9 (60)  
 20–44 113 (85.6) 19 (14.4)   15 (44.1) 19 (55.9)  
 45–64 115 (88.5) 15 (11.5)   9 (39.1) 14 (60.9)  
 >65 52 (92.9) 4 (7.1)   14 (73.7) 5 (26.3)  
Sex        
 M 192 (86.9) 29 (13.1) 0.89§  34 (54) 29 (46) 0.18 
 F 188 (86.2) 30 (13.8)   20 (40) 30 (60)  
Ethnicity**        
 White 248 (86.7) 38 (13.3) 0.2§  40 (48.8) 42 (51.2) 0.66 
 Mixed 2 (100) 0   2 (50) 2 (50)  
 Asian or Asian British 23 (82.1) 5 (17.9)   1 (16.7) 5 (83.3)  
 Black or black British 27 (87.1) 4 (12.9)   8 (50) 8 (50)  
 Chinese or other 12 (66.7) 6 (33.3)   2 (50) 2 (50)  
Etiology        
 Herpes simplex virus 13 (46.4) 15 (53.6) <0.001§  8 (33.3) 16 (66.7) 0.01 
 Varicella zoster virus 25 (89.3) 3 (10.7)   2 (50) 2 (50)  
 Other specified viral 37 (88.1) 5 (11.9)   3 (50) 3 (50)  
 Bacterial 10 (71.4) 4 (28.6)   12 (80) 3 (20)  
 Parasitic 7 (100) 0   2 (100) 0  
 Amoebic 0 0   0 0  
 Fungal 0 0   0 0  
 Immune-mediated 37 (82.2) 8 (17.8)   5 (21.7) 18 (78.3)  
 Unknown 218 (91.2) 21 (8.8)   21 (56.8) 16 (43.2)  
 Other mixed 33 (91.7) 3 (8.3)   1 (50) 1 (50)  
Admission type        
 Elective 119 (95.2) 6 (4.8) 0.001§     
 Emergency 218 (83.5) 43 (16.5)      
 Transfer†† 43 (81.1) 10 (18.9)      
Discharge destination‡‡        
 Home 272 (86.3) 43 (13.7) 0.85§     
 Other hospital/nursing home 37 (84.1) 7 (15.9)      
 Died 40 (85.1) 7 (14.9)      
Treatment specialty        
 Neurosurgery 38 (100) 0 <0.001¶     
 General medicine 65 (81.2) 15 (18.8)      
 Neurology 121 (90.3) 13 (9.7)      
 Pediatrics 27 (73) 10 (27)      
 Pediatric neurology 22 (75.9) 7 (24.1)      
 Infectious diseases 11 (68.8) 5 (31.2)      
 Intensive care medicine 10 (71.4) 4 (28.6)      
 Other 86 (94.5) 5 (5.5)      
Median length of stay, d (range) 11 (0–737);  
n = 351 
31 (0–414);§§ 
 n = 57 
<0.001#     
*Values are no. (%) except as indicated. HES, Hospital Episode Statistics; PHE, Public Health England. 
†Using data from HES. 
‡Using data from the PHE study. 
§Fisher exact test. 
¶2 test. 
#Mann Whitney test. 
**For HES only. n = 312; HES matched, n = 53; PHE only n = 53. 
††Transfer from other hospital, excluding emergency. 
‡‡For HES matched, n = 57. 
§§For HES only, n = 368. 
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study cases included 8 cases also classified as unknown eti-
ology in the PHE study, 8 as immune-mediated, 2 as HSV, 
and 3 as due to other infectious causes.
The initial capture–recapture model estimated that 
348 cases of encephalitis were not registered in either data 
source, giving an estimated number of encephalitis cases for 
the relevant period in that area of 841 (Table 3) and an as-
certainment-adjusted incidence rate of 8.66 cases/100,000 
population/year. The completeness of the 2 sources was es-
timated at 52% for HES and 13% for the PHE study. The 
estimated number of cases for children and adults com-
bined following the stratified analyses (n = 830) was simi-
lar to the overall figure obtained in the crude analysis (n 
= 841); similar results were obtained when the data were 
stratified by region and recombined. When HES data were 
restricted to an encephalitis-specific code recorded in the 
primary diagnostic field, the capture–recapture model esti-
mated 265 unlisted and 612 total encephalitis cases, giving 
an incidence estimate of 6.3 cases/100,000/year and esti-
mated completeness of HES and the PHE study of 47% and 
18%, respectively (Table 3). Similar incidence estimates 
were obtained after excluding from analyses the 2 sites for 
which additional hospitals with potential encephalitis pa-
tients were included in the HES data only (data not shown).
Results of sensitivity analyses to account for poten-
tial overdiagnoses of HES-only encephalitis cases are 
reported in Table 4. By assuming a best estimate PPV 
of 54% for HES-only admissions, the capture–recapture 
model estimated 508 total cases, giving an incidence of 
5.23 cases/100,000/year and an estimated completeness of 
22% for the PHE study; this figure represents our “best 
estimate” of the true incidence of encephalitis in England. 
By assuming a higher PPV for HES-only admissions, the 
number of estimated total cases increased and the com-
pleteness of the PHE study decreased. When HES data 
were restricted to the primary diagnostic field only and a 
PPV of 54% was assumed, the capture–recapture model 
estimated 384 total cases, equivalent to an incidence of 
3.96 cases/100,000/year (Table 4).
Discussion
Our analyses provide estimates of the incidence of 
encephalitis in England attributable to infectious and non-
infectious causes. We present a unique application of cap-
ture–recapture models to estimate the number of cases of 
encephalitis by using an original dataset of well-defined 
and extensively investigated cases of encephalitis.
Multiple scenarios were investigated to assess the sen-
sitivity of the estimates to various assumptions. Depending 
on the scenario, estimated incidence ranged from 2.73 cas-
es/100,000/year to 8.66 cases/105/year; all estimates were 
higher than the 1.5 cases/100,000/year previously reported 
(3). This unique study has brought together 2 distinct data-
sets to help address the inevitable limitations within such 
data sources, particularly those encountered with complex 
syndromes such as encephalitis. We consider our capture–
recapture estimate of 5.23/100,000/year (assuming 54% 
PPV for HES data) to be the best estimate of encephali-
tis incidence in England; this is 3.5 times higher than that 
previously described by Davison et al (3). Our incidence 
analyses update the Davison et al. estimates; diagnostic 
advances, emerging etiologic agents, and introduction of 
new interventions and control strategies (e.g., vaccines) 
are all likely to have affected incidence estimates over 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 19, No. 9, September 2013 1459
 
Table 3. Two-source capture–recapture estimates of encephalitis cases in England, November 1, 2006–October 31, 2007* 
Coding and strata HES only 
PHE study 
only 
Both 
sources 
Estimated total no. 
cases (95% CI) 
% Completeness (95% CI) 
HES PHE study 
Encephalitis-specific code in any of the 20 diagnostic fields     
 Crude analysis 380 54 59 841 (692–991) 52 (43–61) 13 (10–17) 
 Stratified by age group       
  Children <18 y 78 15 20 172 (121–223) 57 (41–73) 20 (12–28) 
  Adults >18 y 290 39 39 658 (512–805) 50 (39–61) 12 (8–15) 
  Total for strata 368 54 59 830 (675–986)   
 Stratified by region       
  London 149 23 16 403 (254–552) 41 (26–56) 10 (5–14) 
  North West 168 29 38 364 (286–442) 57 (45–69) 18 (13–24) 
  South West 63 2 5 96 (49–143) 71 (38–100) 7 (1–14) 
  Total for strata 380 54 59 863 (689–1,038)   
Encephalitis-specific code in primary field only      
 Crude analysis 234 60 53 612 (494–731) 47 (38–56) 18 (14–23) 
 Stratified by age group       
  Children <18 y 49 16 19 126 (87–165) 54 (38–71) 28 (17–39) 
  Adults >18 y 173 44 34 475 (358–593) 44 (33–55) 16 (11–21) 
  Total for strata 222 60 53 601 (478–725)   
 Stratified by region       
  London 86 23 14 265 (159–371) 38 (22–53) 14 (7–21) 
  North West 114 29 34 275 (211–339) 54 (42–66) 23 (16–30) 
  South West 34 2 5 55 (27–83) 71 (38–100) 13 (2–23) 
  Total for strata 234 54 53 595 (469–722)   
*HES, Hospital Episode Statistics; PHE, Public Health England. 
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time. Furthermore, our data included both infectious (not 
just viral) and noninfectious causes of encephalitis, in line 
with the increased recognition of new immune-mediated 
encephalitis etiologies.
A higher incidence (adjusted for year, age, and region) 
of encephalitis was observed among male patients, which is 
consistent with previous studies (12–16). We also observed 
higher incidence of encephalitis among patients <1 and >65 
years of age. Hyporesponsiveness of the immune system in 
early life and later immunosenescence render these groups 
more susceptible to infection, to reactivation of latent in-
fection, or development of encephalitis once infected (17).
Multiple admissions were included in our analyses 
only if they represented different etiologies or occurred >6 
months apart, either of which is not a common occurrence 
in encephalitis as supported by our data. When multiple 
occurrences were excluded, incidence was unchanged. In-
fectious episodes of encephalitis are unlikely to recur in 
the absence of immunosuppression; relapses in immune-
mediated cases are more frequent and were documented in 
the PHE study.
We extended our encephalitis incidence analyses be-
yond the use of HES and linked HES data to PHE study 
data and applied capture–recapture models. The number 
of incident encephalitis admissions recorded in HES was 
considerably higher than the number of cases included in 
the PHE study, even after restricting HES diagnoses to 
the primary diagnostic field. Conversely, nearly half of 
the PHE cases were not captured in HES. The poor agree-
ment between these 2 data sources could have several 
possible reasons.
The likely explanation for nonmatched PHE cases 
is that testing in the PHE study went far beyond routine 
clinical practice, which highlighted the extent to which en-
cephalitis can be underdiagnosed. The higher proportion 
of bacterial cases in the PHE study, classified as menin-
goencephalitis, suggests that these cases may be coded as 
meningitis rather than encephalitis in HES. Also, patients 
with unusual signs and symptoms, such as those with N-
methyl-D-aspartate receptor-antibody encephalitis, which 
typically causes psychiatric symptoms, might not have 
been classified as encephalitis case-patients in HES (18). 
Unfortunately, we could not identify the HES codes used 
for the unmatched PHE cases because the HES data for this 
study included only patients with an encephalitis code.
Unmatched HES cases likely include true encephalitis 
cases not reported to the PHE study team and nonencepha-
litis cases misdiagnosed as encephalitis. Underascertain-
ment in the PHE study is likely, as employing >1 research 
nurse per region to actively identify cases was not finan-
cially feasible: some centers relied on case notification by 
hospital staff alone. The likelihood that HES admissions 
coded as encephalitis included misdiagnoses of syndromes 
with signs that mimic encephalitis is highlighted by the 
PHE study, in which only 54% of suspected encephalitis 
patients initially screened during the 2-year period were ul-
timately included following a rigorous diagnostic process 
(10). The higher proportion of cases of unknown etiology 
in unmatched compared with matched HES admissions and 
their shorter length of hospital stay supports the possibility 
of misdiagnosis and suggests a more likely diagnosis of a 
mimicker syndrome such as septic encephalopathy.
Other reasons for mismatches need consideration. The 
catchment areas covered by the 2 data sources differed 
slightly, but the results of the capture–recapture model did 
not change when we excluded the 2 trusts that had hospitals 
with potential extra encephalitis cases in the HES data. The 
higher number of admissions in HES could be due in part 
to the inclusion of patients with postencephalitic sequelae, 
who would not have been notified to the PHE study. This 
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Table 4. Sensitivity analysis adjusting for variation in positive predictive value for HES-only admissions* 
Positive predictive value, % HES only 
PHE study 
only 
Both 
sources 
Estimated total no. 
cases (95% CI) 
% Completeness (95% CI) Estimated 
incidence HES† PHE study 
Encephalitis-specific code in any of the 20 diagnostic fields     
 30 114 54 59 332 (272–391) 52 (43–61) 34 (27–41) 3.42 
 40 152 54 59 405 (332–477) 52 (43–61) 28 (22–34) 4.17 
 50 190 54 59 477 (392–562) 52 (43–61) 24 (18–29) 4.91 
 54 206 54 59 508 (418–598) 52 (43–61) 22 (17–27) 5.23 
 60 228 54 59 550 (452–648) 52 (43–61) 21 (16–25) 5.67 
 70 266 54 59 623 (512–734) 52 (43–61) 18 (14–22) 6.42 
 80 304 54 59 696 (572–819) 52 (43–61) 16 (12–20) 7.17 
Encephalitis-specific code in primary field only      
 30 71 60 53 265 (214–315) 47 (38–56) 43 (34–51) 2.73 
 40 94 60 53 314 (254–374) 47 (38–56) 36 (28–44) 3.23 
 50 117 60 53 363 (293–433) 47 (38–56) 31 (24–38) 3.74 
 54 127 60 53 384 (310–458) 47 (38–56) 29 (23–36) 3.96 
 60 141 60 53 414 (334–494) 47 (38–56) 27 (21–34) 4.26 
 70 164 60 53 463 (374–553) 47 (38–56) 24 (19–30) 4.77 
 80 188 60 53 514 (415–614) 47 (38–56) 22 (17–27) 5.29 
*Incidence = cases/100,000 population. HES, Hospital Episode Statistics; PHE, Public Health England 
†Due to the Lincoln-Petersen formula, if the number of HES-only admissions varies, the total HES admissions (HES only plus matched) is proportional to 
the estimated total number of cases; hence, the completeness of HES (ratio) does not change with varying positive predictive value.  
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finding is supported by the higher proportion of cases admit-
ted electively and treated under neurosurgery in unmatched 
HES admissions; alternatively, some of these cases could 
be miscoded nonencephalitis mimics, i.e., cases of nosoco-
mial meningitis following surgery.
Three assumptions required for valid capture–recap-
ture estimates also need consideration. First, for a given 
source every patient should have an equal chance of be-
ing ascertained by that source, although different sources 
may have different probabilities of identifying an indi-
vidual case. Our analyses stratified by age or region of 
residence did not indicate any bias in the point estimate 
linked to these variables. Other variables may have influ-
enced the probability of a patient appearing on a list, such 
as ethnicity, sociodemographic factors, or heterogeneity in 
coding between hospitals within regions. Because of the 
small sample sizes, we could not stratify by these variables. 
We did find evidence of heterogeneity in etiology, which 
suggested that in 1 or both datasets, patients with bacte-
rial encephalitis had a different probability of being identi-
fied than did patients with encephalitis of other etiologies, 
which may have led to an overestimate of the number of 
encephalitis cases. Again, performing a stratified analysis 
is not easy, both because of small numbers and because 
we know misclassification and missing data about etiology 
were present and no pathognomonic features exist to allow 
different causes to be distinguished in these cases.
Second, the registers used in capture–recapture should 
be independent; having an encephalitis-specific diagnosis 
in HES should not affect being included in the PHE study 
or vice versa. A patient with suspected encephalitis seen by 
a hospital clinician was likely to be coded as such in HES 
and also be notified to the PHE study. Thus, these sources 
are likely to be positively dependent, and the capture–re-
capture will have underestimated the true number of cases. 
A less likely scenario is that the datasets were negatively 
dependent, for example, if encephalitis cases with bacterial 
etiology were simultaneously more likely to be excluded 
from the HES data and more likely to be included in the 
PHE data. This situation would have led to an overesti-
mate in the number of cases. We did not have access to 
a third data source to evaluate the independence of data 
sources (19). Nevertheless, 2-source capture–recapture can 
indicate an upper or (as is likely here) the lower bound of 
estimates when the direction of dependency is known or 
highly suspected (20).
Third, no false positive cases should occur due to mis-
diagnoses or miscoding. As discussed above, coded HES 
encephalitis cases are likely to have included mimicker 
syndromes, which would inflate the capture–recapture esti-
mate. We addressed this possibility by applying a range of 
PPVs to the HES data; even after assuming a PPV as low 
as 30% for HES-only admissions, the number of cases was 
still higher than previous estimates. A review of medical 
records would be necessary to determine the degree of mis-
diagnosis of true encephalitis cases in HES data. We could 
not do this because HES do not keep patients’ names, and 
use of HES data are subject to strict protocols to prevent 
identification of individual patients.
With a mean length of hospital stay of 34 days, an inci-
dence of 5.23 cases/100,000/year (“best estimate”) equates 
to 90,852 bed-days of hospital occupancy. On the basis of 
a bed-day cost of £261 (US$394 million), the cost to the 
National Health Service would be >£23 million (US$35 
million) per year (21). An incidence of 8.66 cases/100,000/
year, our maximum estimate, would cost almost £40 mil-
lion (US$60 million) per year. The actual cost is likely to 
be higher as patients often require intensive care, costly in-
vestigations, and in-patient rehabilitation. Additional costs 
include long-term care and loss of productivity among 
many working-age survivors.
In summary, the different scenarios used in this study 
provide strong evidence that the incidence of encephalitis 
is higher than that previously estimated in England. This 
higher incidence has clinical, research, and public health 
implications. A diagnosis of encephalitis should be con-
sidered for patients with compatible symptoms, especially 
given the increased recognition of immune-mediated en-
cephalitides for which treatment is available and effective 
if instigated early. Early recognition is important to help 
reduce the substantial economic and societal costs of en-
cephalitis suggested by our study. Stand-alone HES data 
are used extensively for public health research; our anal-
yses highlight the extent to which HES-only data might 
over- or underascertain cases of complex syndromes and 
the advantages of linking these data to other sources to im-
prove incidence estimates. Encephalitis incidence in this 
study was higher than that of other neurologic conditions, 
such as meningococcal meningitis and motor neuron dis-
ease, both of which have a higher profile and public focus 
(22–24). This study highlights the importance of accurate 
diagnosis and coding for complex syndromes with multiple 
etiologies to obtain accurate estimates of incidence and to 
further explore the epidemiology and outcomes of this dev-
astating neurologic illness.
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